Aviceda Therapeutics is winding down after a Phase 2 setback for an eye program intended to move into Phase 3. A source familiar with the decision said the company is now in the process of closing out operations rather than pursuing the planned next-stage trial. The move highlights how pipeline attrition risk continues to weigh on rare ophthalmology-focused development, particularly when mid-stage data does not support advancement. Aviceda had indicated plans to advance to Phase 3 this year despite the setback. For investors and partners, the liquidation of an asset in late pre-Phase 3 territory may create opportunities for competitors to acquire programs or teams, but it also underscores the continuing bar for efficacy signals in degenerative eye disease. The operational shutdown likely concentrates Aviceda’s remaining value in whatever assets can be transferred or retained through closure proceedings.